Pouncing on next-gen I/O play, Sanofi acquires Amunix for $1B+ and picks up 'universal mask' tech
Sanofi is crashing the year-end M&A party with a deal of its own.
Immuno-oncology is the name of the game as it swallows Mountain View, CA-based Amunix for $1 billion upfront and up to $225 million in biobucks, tagging a suite of T cell engagers and cytokine therapies as well as a tech platform for making “conditionally activated biologics.”
“The Amunix technology platform utilizes a next generation smart biologics approach to precisely tailor-deliver medicines to become active only in tumor tissues while sparing normal tissues,” said Sanofi R&D chief John Reed, “thus bringing the promise of more effective and safer treatment options for cancer patients.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 158,500+ biopharma pros reading Endpoints daily — and it's free.